In vivo activity of JNJ-28871063 in human tumor xenograft models
All dosing was carried out in groups of 8 mice. TGI was calculated as the difference between the change in control and drug-treated tumor volumes on the last day of the study. Statistical significance was evaluated by comparing the mean tumor size of control groups with drug-treated groups using a two-tailed Student's t test.
Graph | Tumor Type | Compound | Dose | Route | Schedule | TGI | P Value |
|---|---|---|---|---|---|---|---|
| mg/kg | % | ||||||
| A | N87 | JNJ-28871063 | 100 | p.o. | qd × 35 | 71.0 | 0.006 |
| A | N87 | Trastuzumab | 20 | i.p. | biw × 4 | 11.41 | 0.486 |
| B | N87 | JNJ-28871063 | 100 | p.o. | qd × 30 | 69.4 | 0.003 |
| B | N87 | Gefitinib | 100 | p.o. | qd × 30 | 36.35 | 0.403 |
| B | N87 | Lapatinib | 100 | p.o. | qd × 30 | 70.1 | 0.029 |
| C | A431 | JNJ-28871063 | 100 | p.o. | qd × 25 | 66.8 | 0.025 |
| C | A431 | Gefitinib | 100 | p.o. | qd × 25 | 94.5 | 0.002 |
| C | A431 | Lapatinib | 100 | p.o. | qd × 25 | 9.4 | 0.596 |
| D | BT474 | JNJ-28871063 | 200 | p.o. | bid × 30 | 61.8 | 0.035 |
| D | BT474 | Lapatinib | 100 | p.o. | bid × 30 | 76.9 | 0.049 |
| D | BT474 | Trastuzumab | 12.5 | i.p. | biw × 4 | 65.8 | 0.06 |
p.o., oral gavage; i.p., intraperitoneal; qd, every day; bid, twice per day; biw, twice per week.